LENSAR

LENSAR P/B

The P/B (Price-to-Book Ratio) of LENSAR (LNSR) as of Oct 18, 2026 is -5.61. In the previous year, P/B (Price-to-Book Ratio) was 7.83 — a change of -171.66% (lower).

P/B

-5.61

YoY

-171.66%

Last updated:

P/B (Price-to-Book Ratio) of LENSAR is 2025 -5.61 . P/B (Price-to-Book Ratio) of LENSAR was 2024 7.83 . It decreases by -171.66% lower compared to the previous year.

The LENSAR P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
-7.14 USD
Jan 1, 2019
-4.78 USD
Jan 1, 2020
2.17 USD
Jan 1, 2021
2.66 USD
Jan 1, 2022
3.48 USD
Jan 1, 2023
3.10 USD
Jan 1, 2024
7.83 USD
Jan 1, 2025
-5.61 USD
The LENSAR P/B history
YEARP/BYoY
-5.61-171.66%
7.83+153.01%
3.10-11.01%
3.48+30.71%
2.66+22.47%
2.17-145.46%
-4.78-33.02%
-7.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR Inc is a healthcare company based in Orlando, Florida, specializing in femtosecond laser technology for refractive cataract surgery. The company went public on September 21, 2020, and currently employs 150 full-time employees. LENSAR develops and markets femtosecond laser systems designed to treat cataracts and manage pre-existing or surgically induced corneal astigmatism. Its primary products include the LENSAR Laser System, which features Streamline IV and IntelliAxis technologies, along with associated consumable components such as a disposable patient interface device kit. The company also offers the ALLY Adaptive Cataract Treatment System, a compact device integrating femtosecond laser capabilities with enhanced laser features for single-room cataract procedures. LENSAR's technology aims to assist surgeons in achieving optimal visual outcomes during cataract surgery. The company operates within the healthcare sector, focusing on innovative solutions for ophthalmic procedures. Its headquarters in Orlando serves as the central hub for research, development, and business operations. LENSAR's website, lensar.com, provides further details about its products and services. The firm's product portfolio emphasizes precision and efficiency in surgical treatments, targeting healthcare providers seeking advanced tools for cataract management. As a publicly traded entity under the ticker LNSR, LENSAR continues to advance its technological offerings in the medical device industry. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

P/B (Price-to-Book Ratio) of LENSAR is -5.61 in 2025.

P/B (Price-to-Book Ratio) of LENSAR changed from 7.83 to -5.61, representing a -171.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) LENSAR since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s LENSAR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LENSAR

All Key Metrics — LENSAR